P
Philipp Dahm
Researcher at University of Minnesota
Publications - 404
Citations - 24636
Philipp Dahm is an academic researcher from University of Minnesota. The author has contributed to research in topics: Evidence-based medicine & Randomized controlled trial. The author has an hindex of 52, co-authored 359 publications receiving 19564 citations. Previous affiliations of Philipp Dahm include University of Florida & American Urological Association.
Papers
More filters
Journal ArticleDOI
GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables
Gordon H. Guyatt,Andrew D Oxman,Elie A. Akl,Regina Kunz,Gunn Elisabeth Vist,Jan Brozek,Susan L Norris,Yngve Falck-Ytter,Paul Glasziou,Hans deBeer,Roman Jaeschke,David Rind,Joerg J Meerpohl,Philipp Dahm,Holger J. Schünemann +14 more
TL;DR: The GRADE process begins with asking an explicit question, including specification of all important outcomes, and provides explicit criteria for rating the quality of evidence that include study design, risk of bias, imprecision, inconsistency, indirectness, and magnitude of effect.
Journal ArticleDOI
GRADE guidelines: 7. Rating the quality of evidence—inconsistency
Gordon H. Guyatt,Andrew D Oxman,Regina Kunz,James Woodcock,Jan Brozek,Mark Helfand,Pablo Alonso-Coello,Paul Glasziou,Roman Jaeschke,Elie A. Akl,Susan L Norris,Gunn Elisabeth Vist,Philipp Dahm,Vijay K Shukla,Julian P T Higgins,Yngve Falck-Ytter,Holger J. Schünemann +16 more
TL;DR: Credibility is increased if subgroup effects are based on a small number of a priori hypotheses with a specified direction; subgroup comparisons come from within rather than between studies; tests of interaction generate low P-values; and have a biological rationale.
Journal ArticleDOI
Screening for prostate cancer.
TL;DR: There is insufficient evidence to either support or refute the routine use of mass, selective or opportunistic screening compared to no screening for reducing prostate cancer mortality, and no robust evidence is available regarding the impact of screening on quality of life, harms of screening, or its economic value.
Journal ArticleDOI
GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations
Jeffrey C Andrews,Gordon H. Guyatt,Andrew D Oxman,Phil Alderson,Philipp Dahm,Yngve Falck-Ytter,Mona Nasser,Joerg J Meerpohl,Piet N. Post,Regina Kunz,Jan Brozek,Gunn Elisabeth Vist,David Rind,Elie A. Akl,Holger J. Schünemann +14 more
TL;DR: The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to classifying the direction and strength of recommendations is described, separated into strong and weak.
Journal ArticleDOI
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells
Jens Dannull,Zhen Su,David A. Rizzieri,Benjamin K. Yang,Doris Coleman,Donna Yancey,Aijing Zhang,Philipp Dahm,Nelson J. Chao,Eli Gilboa,Johannes Vieweg +10 more
TL;DR: It is shown that DAB(389)IL-2 is capable of selectively eliminating CD25-expressing Tregs from the PBMCs of cancer patients without inducing toxicity on other cellular subsets with intermediate or low expression of CD25.